Vimarsana
Biggest News Aggregation in the World

Critical Limb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Critical Limb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Critical Limb Today - Breaking & Trending Today

Critical Limb Ischemia Or Rest Pain: All You Need to Know - Vimarsana News

Critical Limb Ischemia Or Rest Pain: All You Need to Know

Critical limb ischemia (CLI) can lead to limb amputation, if left untreated. Read on to know what is Critical Limb Ischemia and how it is treated. TheHealthSite.com

Blood-Disease Breakthrough Tested In New Haven - Vimarsana News

Blood-Disease Breakthrough Tested In New Haven

A nonagenarian is waiting in New Haven for three five-milliliter syringes to arrive from overseas — and help her walk outside the house again and avoid…

Hemostemix Inc.: Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials - Vimarsana News

Hemostemix Inc.: Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead

Hemostemix Inc.: Hemostemix Announces Presentation to the Emerging Growth Conference - Vimarsana News

Hemostemix Inc.: Hemostemix Announces Presentation to the Emerging Growth Conference

Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors

Hemostemix Inc.: Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market - Vimarsana News

Hemostemix Inc.: Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market

Calgary, Alberta--(Newsfile Corp. - October 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") and its wholly-owned subsidiary, PreCerv Inc., are pleased